XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise to advance XBiotech's development of True Human antibody therapies. Dr. Shivaswamy has been with the company for 17 years and served as interim CEO since December 2025, while Simard brings experience in clinical development and research. Together, they plan to drive innovation and deliver sustainable value to patients and shareholders.
Regarding the leadership change at XBiotech, here is Pluang's market snapshot for health-sector stocks as of Oct 24, 2026 20:02 WIB: Of 150 priced US health-sector stocks, 44 rose and 105 fell today. Notable movers include WGS at USD 56.15 with a 1-day change of -16.37%, CTXR at USD 0.40 up 8.79%, and LQDA at USD 42.65 up 7.46%. The most notable figure is WGS's 16.37% decline.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
With the Federal Reserve continuing to hike interest rates rather than cut them, floating rate ETFs like the State Street SPDR Blackstone Senior Loan ETF (SRLN) have become attractive fixed income options. SRLN provides a 7.19% SEC yield, near-zero d...
